Y-box binding protein-1 (YB-1) promotes cell cycle progression through CDC6-dependent pathway in human cancer cells

European Journal of Cancer

Volumn 46, Issue 5, 2010, Pages 954-965

  Basaki, Yuji ^a   Taguchi, Ken ichi ^b   Izumi, Hiroto ^c   Murakami, Yuichi ^a   Kubo, Takuya ^a   Hosoi, Fumihito ^a   Watari, Kosuke ^a   Nakano, Kenji ^a   Kawaguchi, Hidetoshi ^b   Ohno, Shinji ^b   Kohno, Kimitoshi ^b   Ono, Mayumi ^a   Kuwano, Michihiko ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b NATIONAL KYUSHU CANCER CENTER   (Japan)

^c UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

CDC6; Cell cycle regulation; YB 1

Indexed keywords

CELL CYCLE PROTEIN 6; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 2A; SMALL INTERFERING RNA; Y BOX BINDING PROTEIN 1;

ARTICLE; BREAST CANCER; CANCER GROWTH; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; BREAST NEOPLASMS; CELL CYCLE; CELL CYCLE PROTEINS; CELL PROLIFERATION; FEMALE; HUMANS; JAPAN; MIDDLE AGED; NUCLEAR PROTEINS; TUMOR MARKERS, BIOLOGICAL; Y-BOX-BINDING PROTEIN 1; YOUNG ADULT;

EID: 77349094312     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2009.12.024     Document Type: Article

References (42)

1. Matsumoto K., and Wolffe A.P. Gene regulation by Y-box proteins: coupling control of transcription and translation. Trends Cell Biol 8 (1998) 318-333
2. Kohno K., Izumi H., Uchiumi T., Ashizuka M., and Kuwano M. The pleiotropic functions of the Y-box-binding protein, YB-1. Bioessays 25 (2003) 691-698
3. Asakuno K., Kohno K., Uchiumi T., et al. Involvement of a DNA binding protein, MDR-NF1/YB-1, in human MDR1 gene expression by actinomycin D. Biochem Biophys Res Commun 199 (1994) 1428-1435
4. Ohga T., Koike K., Ono M., et al. Role of the human Y box-binding protein YB-1 in cellular sensitivity to the DNA-damaging agents cisplatin, mitomycin C, and ultraviolet light. Cancer Res 56 (1996) 4224-4228
5. Bargou R.C., Jürchott K., Wagener C., et al. Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expression. Nat Med 3 (1997) 447-450
6. Oda Y., Sakamoto A., Shinohara N., et al. Nuclear expression of YB-1 protein correlates with P-glycoprotein expression in human osteosarcoma. Clin Cancer Res 4 (1998) 2273-2277
7. Kamura T., Yahata H., Amada S., et al. Is nuclear expression of Y-box binding protein-1 a new prognostic factor in ovarian serous adenocarcinoma?. Cancer 85 (1999) 2450-2454
8. Oda Y., Ohishi Y., Saito T., et al. Nuclear expression of Y-box-binding protein-1 correlates with P-glycoprotein and topoisomerase II alpha expression, and with poor prognosis in synovial sarcoma. J Pathol 199 (2003) 251-258
9. Huang X., Ushijima K., Komai K., et al. Co-expression of Y-box binding protein-1 and P-glycoprotein as a prognostic marker for survival in epithelial ovarian cancer. Gynecol Oncol 93 (2004) 287-291
10. Giménez-Bonafé P., Fedoruk M.N., Whitmore T.G., et al. YB-1 is upregulated during prostate cancer tumor progression and increases P-glycoprotein activity. Prostate 59 (2004) 337-349
11. Oda Y., Ohishi Y., Basaki Y., et al. Prognostic implications of the nuclear localization of Y-box-binding protein-1 and CXCR4 expression in ovarian cancer: their correlation with activated Akt, LRP/MVP and P-glycoprotein expression. Cancer Sci 98 (2007) 1020-1026
12. Kuwano M., Oda Y., Izumi H., et al. The role of nuclear Y-box binding protein 1 as a global marker in drug resistance. Mol Cancer Ther 3 (2004) 1485-1492
13. Lu Z.H., Books J.T., and Ley T.J. YB-1 is important for late-stage embryonic development, optimal cellular stress responses, and the prevention of premature senescence. Mol Cell Biol 25 (2005) 4625-4637
14. Uchiumi T., Fotovati A., Sasaguri T., et al. YB-1 is important for an early stage embryonic development: neural tube formation and cell proliferation. J Biol Chem 281 (2006) 40440-40449
15. Bergmann S., Royer-Pokora B., Fietze E., et al. YB-1 provokes breast cancer through the induction of chromosomal instability that emerges from mitotic failure and centrosome amplification. Cancer Res 65 (2005) 4078-4087
16. Sutherland B.W., Kucab J., Wu J., et al. Akt phosphorylates the Y-box binding protein 1 at Ser 102 located in the cold shock domain and affects the anchorage-independent growth of breast cancer cells. Oncogene 24 (2005) 4281-4292
17. Basaki Y., Hosoi F., Oda Y., et al. Akt-dependent nuclear localization of Y-box-binding protein 1 in acquisition of malignant characteristics by human ovarian cancer cells. Oncogene 26 (2007) 2736-2746
18. Fujii T., Kawahara A., Basaki Y., et al. Expression of HER2 and estrogen receptor alpha depends upon nuclear localization of Y-box binding protein-1 in human breast cancers. Cancer Res 68 (2008) 1504-1512
19. Lee C., Dhillon J., Wang M.Y., et al. Targeting YB-1 in HER-2 overexpressing breast cancer cells induces apoptosis via the mTOR/STAT3 pathway and suppresses tumor growth in mice. Cancer Res 68 (2008) 8661-8666
20. Shiota M., Izumi H., Onitsuka T., et al. Twist promotes tumor cell growth through YB-1 expression. Cancer Res 68 (2008) 98-105
21. Chatterjee M., Rancso C., Stühmer T., et al. The Y-box binding protein YB-1 is associated with progressive disease and mediates survival and drug resistance in multiple myeloma. Blood 111 (2008) 3714-3722
22. Jurchott K., Bergmann S., Stein U., et al. YB-1 as a cell cycle-regulated transcription factor facilitating cyclin A and B1 gene expression. J Biol Chem 278 (2003) 27988-27996
23. Berquin I.M., Pang B., Dziubinski M.L., et al. Y-box-binding protein 1 confers EGF independence to human mammary epithelial cells. Oncogene 24 (2005) 3177-3186
24. Wu J., Lee C., Yokom D., et al. Disruption of the Y-box binding protein-1 results in suppression of the epidermal growth factor receptor and HER-2. Cancer Res 66 (2006) 4872-4879
25. Evdokimova V., Tognon C., Ng T., et al. Translational activation of snail1 and other developmentally regulated transcription factors by YB-1 promotes an epithelial-mesenchymal transition. Cancer Cell 15 (2009) 402-415
26. Mailand N., and Diffley J.F. CDKs promote DNA replication origin licensing in human cells by protecting Cdc6 from APC/C-dependent proteolysis. Cell 122 (2005) 915-926
27. Takeda D.Y., Shibata Y., Shibata Y., Parvin J.D., and Dutta A. Recruitment of ORC or CDC6 to DNA is sufficient to create an artificial origin of replication in mammalian cells. Genes Dev 19 (2005) 2827-2836
28. Randell J.C., Bowers J.L., Rodriguez H.K., Sequential Bell.S.P., and TP A. Hydrolysis by Cdc6 and ORC directs loading of the Mcm2-7 helicase. Mol Cell 21 (2006) 29-39
29. Cook J.G., Park C.H., Burke T.W., et al. Analysis of Cdc6 function in the assembly of mammalian prereplication complexes. Proc Natl Acad Sci USA 99 (2002) 1347-1352
30. Stillman B. Origin recognition and the chromosome cycle. FEBS Lett 579 (2005) 77-84
31. Petersen B.O., Wagener C., Marinoni F., et al. Cell cycle- and cell growth-regulated proteolysis of mammalian CDC6 is dependent on APC-CDH1. Genes Dev 14 (2000) 2330-2343
32. Gonzalez S., Klatt P., Delgado S., et al. Oncogenic activity of Cdc6 through repression of the INK4/ARF locus. Nature 440 (2006) 702-706
33. Romagnoli S., Fasoli E., Vaira V., et al. Identification of potential therapeutic targets in malignant mesothelioma using cell-cycle gene expression analysis. Am J Pathol 174 (2009) 762-770
34. Harvey J.M., Clark G.M., Osborne C.K., and Allred D.C. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17 (1999) 1474-1481
35. Sherr C.J., and Roberts J.M. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 13 (1999) 1501-1512
36. Sherr C.J. Mammalian G1 cyclins. Cell 73 (1993) 1059-1065
37. Ball K.L., Lain S., Fâhraeus R., Smythe C., and Lane D.P. Cell-cycle arrest and inhibition of Cdk4 activity by small peptides based on the carboxy-terminal domain of p21WAF1. Curr Biol 7 (1997) 71-80
38. Chen W.J., Chang C.Y., and Lin J.K. Induction of G1 phase arrest in MCF human breast cancer cells by pentagalloylglucose through the down-regulation of CDK4 and CDK2 activities and up-regulation of the CDK inhibitors p27(Kip) and p21(Cip). Biochem Pharmacol 65 (2003) 1777-1785
39. Feng L., Barnhart J.R., Seeger R.C., et al. Cdc6 knockdown inhibits human neuroblastoma cell proliferation. Mol Cell Biochem 311 (2008) 189-197
40. Shibahara K., Sugio K., Osaki T., et al. Nuclear expression of the Y-box -binding protein, YB-1 as a novel marker of disease progression in non-small cell lung cancer. Clin Cancer Res 7 (2001) 3151-3155
41. Kashihara M., Azuma K., Kawahara A., et al. Nuclear Y-box binding protein-1, a predictive marker of prognosis, is correlated with expression of HER2/ErbB2 and HER3/ErbB3 in non-small cell lung cancer. J Thorac Oncol 4 (2009) 1066-1074
42. Faury D., Nantel A., Dunn S.E., et al. Molecular profiling identifies prognostic subgroups of pediatric glioblastoma and shows increased YB-1 expression in tumors. J Clin Oncol 25 (2007) 1196-1208